Title
Use of third line antiretroviral therapy in Latin America
Date Issued
15 September 2014
Access level
open access
Resource Type
journal article
Author(s)
Cesar C.
Shepherd B.E.
Jenkins C.A.
Ghidinelli M.
Castro J.L.
Veloso V.G.
Cortes C.P.
Padgett D.
Crabtree-Ramirez B.
Fink V.
Duran A.
Sued O.
McGowan C.C.
Cahn P.
Madero J.S.
Grinsztejn B.
Reyes M.W.
Pape J.W.
Publisher(s)
Public Library of Science
Abstract
Background: Access to highly active antiretroviral therapy (HAART) is expanding in Latin America. Many patients require second and third line therapy due to toxicity, tolerability, failure, or a combination of factors. The need for third line HAART, essential for program planning, is not known.
Volume
9
Issue
9
Language
English
OCDE Knowledge area
Salud pública, Salud ambiental
Virología
Scopus EID
2-s2.0-84907164582
PubMed ID
Source
PLoS ONE
ISSN of the container
19326203
Sponsor(s)
The authors have read the journal's policy and the authors of this manuscript have the following competing interests: Eduardo Gotuzzo received honoraria as a board member of Janssen, Pfizer, and Johnson & Johnson; and received a grant from University of New South Wales. Omar Sued received honoraria for consultancy from Aztra Zeneca; received grants from Abbie and Merck; received payment for lectures from Abbie; and received support for travelling from Merck and Glaxo. Pedro Cahn received honoraria for consultancy from Abbie, Merck and ViiV and received grants from Abbie and Merck. Omar Sued is a PLOS ONE Editorial Board member. This does not alter the authors' adherence to PLOS ONE Editorial policies and criteria. For the remaining authors none were declared.
We gratefully acknowledge all patients, caregivers, and data managers involved in the CCASAnet cohorts. This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) as part of the International Epidemiologic Databases to Evaluate AIDS (IeDEA): U01 AI069923.
Sources of information:
Directorio de Producción Científica
Scopus